Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 2959-2966

  Arab Alameddine, Mona ^a,b   Fayet Mello, Aurélie ^a   Lubomirov, Rubin ^a   Neely, Michael ^c   Di Iulio, Julia ^a   Owen, Andrew ^d   Boffito, Marta ^f   Cavassini, Matthias ^a   Günthard, Huldrych F ^e   Rentsch, Katharina ^e   Buclin, Thierry ^a   Aouri, Manel ^a   Telenti, Amalio ^a   Decosterd, Laurent Arthur ^a   Rotger, Margalida ^a   Csajka, Chantal ^a,b   Battegay, M ^g   Bernasconi, E ^g   Boni J ^g   Bucher, H C ^g   Burgisser P ^g   Calmy, A ^g   Cattacin, S ^g   Cavassini, M ^g   Dubs, R ^g   Egger, M ^g   Elzi, L ^g   Fischer, M ^g   Flepp, M ^g   Fontana, A ^g   Francioli, P ^g   Furrer, H ^g   Fux, C A ^g   Gorgievski, M ^g   Hirsch, H H ^g   Hirschel, B ^g   Hosli I ^g   Kahlert, C ^g   Kaiser, L ^g   Karrer, U ^g   Kind, C ^g   Klimkait, T ^g   Ledergerber, B ^g   Martinetti, G ^g   Muller N ^g   Nadal, D ^g   Paccaud, F ^g   Pantaleo, G ^g   Rauch, A ^g   Regenass, S ^g   Rickenbach, M ^g   Rudin, C ^g   Schmid, P ^g   Schultze, D ^g   Schupbach J ^g   Speck, R ^g   De Tejada, B M ^g   Taffe P ^g   Telenti, A ^g   Trkola, A ^g   Vernazza, P ^g   Weber, R ^g   Yerly, S ^g   more..

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f Chelsea and Westminster Foundation Trust   (United Kingdom)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; BILIRUBIN; GLUCURONOSYLTRANSFERASE; RALTEGRAVIR;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; COMPARTMENT MODEL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG GLUCURONIDATION; DRUG MONITORING; FEMALE; GENDER; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; SIMULATION; UGT1A9 3 GENE;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MODELS, THEORETICAL; PHARMACOGENETICS; RITONAVIR; YOUNG ADULT;

EID: 84861168106     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05424-11     Document Type: Article

References (49)

1. Anderson MS, et al. 2008. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob. Agents Chemother. 52:4228-4232.
2. Ashby J, et al. 2011. Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers. J. Antimicrob. Chemother. 66:1340-1345.
3. Baroncelli S, et al. 2010. Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration. Ann. Pharmacother. 44:838-843.
4. Bernard O, Guillemette C. 2004. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab. Dispos. 32:775-778. (Pubitemid 38955603)
5. Brainard DM, et al. 2011. Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics. J. Clin. Pharmacol. 51:422-427.
6. Brainard DM, Wenning LA, Stone JA, Wagner JA, Iwamoto M. 2011. Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor. J. Clin. Pharmacol. 51:1376-1402.
7. Brown KC, Paul S, Kashuba AD. 2009. Drug interactions with new and investigational antiretrovirals. Clin. Pharmacokinet. 48:211-241.
8. Burger DM. 2010. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies. Expert Opin. Drug Metab. Toxicol. 6:1151-1160.
9. Cattaneo D, et al. 2012. Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. J. Antimicrob. Chemother. 67:460-464.
10. Cattaneo D, et al. 2010. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients. Ther. Drug Monit. 32:782-786.
11. Croxtall JD, Scott LJ. 2010. Raltegravir: in treatment-naive patients with HIV-1 infection. Drugs 70:631- 642.
12. da Silva D, et al. 2010. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. J. Antimicrob. Chemother. 65:1262-1269.
13. de Bakker PIW, et al. 2005. Efficiency and power in genetic association studies. Nat. Genet. 37:1217-1223.
14. Eron JJ, Jr et al. 2011. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect. Dis. 11:907-915.
15. Fayet A, et al. 2009. A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: raltegravir, maraviroc, darunavir, and etravirine. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 877: 1057-1069.
16. Fayet-Mello A, et al. 2011. Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration. J. Antimicrob. Chemother. 66:1573-1581.
17. Iwamoto M, et al. 2008. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin. Infect. Dis. 47:137-140. (Pubitemid 351920602)
18. Iwamoto M, et al. 2009. Effects of omeprazole on plasma levels of raltegravir. Clin. Infect. Dis. 48:489-492.
19. Iwamoto M, et al. 2008. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob. Agents Chemother. 52: 4338-4343.
20. Iwamoto M, et al. 2008. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin. Pharmacol. Ther. 83:293-299.
21. Johnson JA. 2000. Predictability of the effects of race or ethnicity on pharmacokinetics of drugs. Int. J. Clin. Pharmacol. Ther. 38:53- 60.
22. Kassahun K, et al. 2007. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab. Dispos. 35:1657-1663. (Pubitemid 47296061)
23. Konturek JW, Fischer H, van der Voort IR, Domschke W. 1997. Disturbed gastric motor activity in patients with human immunodeficiency virus infection. Scand. J. Gastroenterol. 32:221-225.
24. Levesque E, et al. 2007. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin. Pharmacol. Ther. 81:392- 400.
25. Lou XY, et al. 2007. A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence. Am. J. Hum. Genet. 80:1125-1137.
26. Menard V, Girard H, Harvey M, Perusse L, Guillemette C. 2009. Analysis of inherited genetic variations at the UGT1 locus in the French-Canadian population. Hum. Mutat. 30:677-687.
27. Merck Sharp and Dohme. 2010. Isentress prescribing information. Merck & Co., Whitehouse Station, NJ.
28. Molto J, et al. 2011. Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients. Antimicrob. Agents Chemother. 55:72-75.
29. Neely M, et al. 2010. Pharmacokinetics and pharmacogenomics of once daily raltegravir and atazanavir in healthy volunteers. Antimicrob. Agents Chemother. 54:4619-4625.
30. Neild PJ, et al. 2000. Delayed gastric emptying in human immunodeficiency virus infection: correlation with symptoms, autonomic function, and intestinal motility. Dig. Dis. Sci. 45:1491-1499.
31. Nicolas JM, Espie P, Molimard M. 2009. Gender and interindividual variability in pharmacokinetics. Drug Metab. Rev. 41:408-421.
32. Powderly WG. 2010. Integrase inhibitors in the treatment of HIV-1 infection. J. Antimicrob. Chemother. 65:2485-2488.
33. Purcell S, et al. 2007. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81:559-575. (Pubitemid 47330214)
34. Rotger M, Csajka C, Telenti A. 2006. Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents. Curr. HIV/AIDS Rep. 3:118-125. (Pubitemid 44874997)
35. Scherrer AU, et al. 2010. Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures. J. Acquir. Immune Defic. Syndr. 53:464-471.
36. Soldin OP, Mattison DR. 2009. Sex differences in pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 48:143-157.
37. Stephens M, Donnelly P. 2003. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. 73:1162-1169. (Pubitemid 37414228)
38. Stephens M, Smith NJ, Donnelly P. 2001. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68: 978-989. (Pubitemid 32289743)
39. Tamura K, Dudley J, Nei M, Kumar S. 2007. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol. Biol. Evol. 24:1596 -1599.
40. Teppler H, et al. 2011. Long-term safety from the raltegravir clinical development program. Curr. HIV Res. 9:40 -53.
41. Ter Heine R, et al. 2009. Identification and profiling of circulating metabolites of atazanavir, a HIV protease inhibitor. Drug Metab. Dispos. 37:1826 -1840.
42. Umeh OC, Currier JS. 2006. Sex differences in pharmacokinetics and toxicity of antiretroviral therapy. Expert Opin. Drug Metab. Toxicol. 2:273-283. (Pubitemid 46372369)
43. U.S. Department of Health and Human Services. 2009. Common Terminology Criteria for Adverse Events (CTCAE). http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4. 03-2010-06-14-QuickReference-5x7.pdf. U.S. Department of Health and Human Services, Washington, DC.
44. U.S. Department of Health and Human Services. 2010. Panel on Anti-retroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. U.S. Department of Health and Human Services, Washington, DC.
45. Villeneuve L, Girard H, Fortier LC, Gagne JF, Guillemette C. 2003. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J. Pharmacol. Exp. Ther. 307:117-128.
46. Wang L, et al. 2011. Pharmacokinetic modeling of plasma and intracellular concentrations of raltegravir in healthy volunteers. Antimicrob. Agents Chemother. 55:4090-4095.
47. Wenning LA, et al. 2008. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob. Agents Chemother. 52:3253-3258.
48. Wenning LA, et al. 2009. Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms. Clin. Pharmacol. Ther. 85:623- 627.
49. Zhu L, et al. 2010. Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals. Antivir. Ther. 15: 1107-1114.